Top Pharmaceutical Companies in Boston, MA (130)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Customer Loyalty & Retention: Autoship accounts for the vast majority of sales (over four-fifths) and is growing faster than total revenue, indicating a sticky, recurring base and higher retention. Evidence includes Autoship representing ~83% of FY2025 net sales and ~84.6% in Q2 FY2026 with high single‑digit to double‑digit growth.
Profitability: Operating metrics show expanding earnings power, with adjusted EBITDA up materially and margins improving alongside strong free cash flow. Observations include FY2025 adjusted EBITDA growth of ~26% with margin expansion and additional year‑over‑year gains reported in 1H FY2026.
Strong Market Position & Advantage: Chewy is characterized as the largest U.S. pet e‑tailer and a leading online pet‑supplies platform by GMV and digital presence, underpinning durable scale advantages. Multiple summaries highlight leadership in online pet retail, substantial Autoship penetration, and strong digital search share versus specialty peers.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.
Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.
Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.
Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.
Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.
The AMR Action Fund is a groundbreaking VC fund that enables breakthroughs in the development of antibiotics, anti-fungals, and other antimicrobials. We invest in companies developing innovative treatments for priority drug-resistant pathogens and advocate for market reforms and policy solutions to change how society values these lifesaving drugs
EdenRoc Sciences is a privately-held biotechnology company formed to cultivate world-class life sciences start-up companies. EdenRoc specializes in enabling efficient translation of top tier academic and government science into technologies which provide novel and cutting-edge research tools, diagnostics, and pharmaceuticals.
Endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind, to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE® platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely...
Endpoint Clinical, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is repeatedly characterized as a global leader in RTSM/IRT with substantial operating scale, supporting 2,000+ studies across 90+ countries and 800+ active studies. This breadth and ability to handle complex, global trials provide a durable competitive edge.
Investor Backing & Capital Strength: The June 2024 acquisition by Arsenal Capital Partners supplies focused capital and sponsor support to accelerate expansion and innovation. This backing is presented as validation of market position and a catalyst for the next phase of growth.
Innovation-Driven Growth: Five generations of purpose-built RTSM platforms and the proprietary PULSE platform, including faster study builds in four weeks or less, indicate sustained product advancement. A 2025 brand refresh and continued tech investment underscore a roadmap aimed at pushing RTSM forward.
OCB Eye Health Services provided patients with medical laser and surgical eye care of the highest quality. In addition to eye examinations, our ophthalmologists provide care in the following specialties: cataract, glaucoma, cornea, diseases of the retina, orbital plastics, pediatrics, LASIK refractive surgery and eye trauma. Our staff of 30 ophthalmologists and 13 optometrists care for over 165,000 patients each...
Multiply Labs develops advanced robotic systems that manufacture individualized drugs at scale. Our products are enabled by the combination of pharmaceutical science with robotics technology. Multiply Labs has built and operates a unique robotic pharmaceutical manufacturing facility in San Francisco.
The Pharmacy Benefits Savings Experts Scripta is a unique company dedicated to stopping out of control pharmacy benefit spending before it starts for self-insured employers. Our exclusive software analyzes all pharmacy transactions every month, compares them to your PBM contract, and to our exclusive Med Mapping Software. The result? A level of transparency and cost-control never before available to payers. Our...
The National MS Society is a non-profit organization dedicated to curing multiple sclerosis while empowering people affected by the disease to live their best lives through research, education, and support.
Ovid Therapeutics is a biopharmaceutical company striving to calm the storm that causes seizures by developing new medicines for epilepsies and brain conditions. For those who need relief, we must succeed—their hopes are our aspirations. We act with urgency, ingenuity and integrity as we seek a future free of seizures. At Ovid, we are pursuing small molecule compounds with untapped...
Cerevel Therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). The company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders, including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area,...
Massachusetts College of Pharmacy and Health Sciences (MCPHS) is an innovator in health and professional education, preparing future generations of global leaders to improve public health. With over 7,000 students across campuses in Boston, Worcester, and Manchester, MCPHS is one of the largest and most highly-ranked institutions for health and life sciences, dedicated to advancing the healthcare landscape through education...
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of...
For nearly a decade, KalVista Pharmaceuticals has been focused on addressing the critical unmet needs of those living with hereditary angioedema (HAE). With more than 250 employees worldwide, we leverage our team’s vast knowledge and expertise across all aspects of research, development, and commercialization to redefine the future of HAE treatment and advance global care for those who need it most.
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...
Merck's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.
Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.
Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. We are powered...
Novo Nordisk's Top Stability & Growth Strengths
Strong Market Position & Advantage: Novo Nordisk is characterized as a global leader in GLP‑1–based diabetes and obesity care, anchored by clinically differentiated products like Wegovy and a broad GLP‑1 portfolio. While shares fluctuate by geography, disclosures and independent analyses continue to frame the company as a category leader.
Innovation-Driven Growth: Cardiovascular outcomes data supporting Wegovy’s label expansion and the first approved oral GLP‑1 for chronic weight management, together with late‑stage assets (e.g., amycretin/zenagamtide, CagriSema), strengthen adoption arguments and extend the franchise.
Market Expansion: U.S. launch momentum for the Wegovy pill, EU approval, and planned international rollouts in 2026 are broadening access and the addressable market. Significant capacity additions, including acquired fill‑finish sites and new investments, are intended to support higher volumes across regions.
We are a biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. We consistently embrace opportunities to improve the lives of our patients, their caregivers, our communities, our partners, and each other.
The Bill & Melinda Gates Medical Research Institute is a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited. The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities, including pre-clinical development, full clinical development (from phase...
Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of patients with underserved conditions. As an industry leader in providing unique, accessible, and high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company’s patient-centric products span...
